A Study of SYS6010 and Platinum-based Chemotherapy in Patients With EGFR-mutated NSCLC.
Status:
NOT_YET_RECRUITING
Trial end date:
2026-08-30
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of SYS6010 versus platinum-based chemotherapy in participants with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC)